000			03886nam a22004571i 4500
999			_c119153 _d119153 _x1
001			119153
003			ES-MaUEC
005			20230207040635.0
006			a|||| o|||| 00| 0
007			cr nn nnnaamaa
008			200318s2020 gw | o |||| 0|eng d
020			_a9783030359102
024	7		_a10.1007/978-3-030-35910-2 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
041	0		_aeng
050		4	_aRS210 _b2020 EB
245	0	0	_aMucosal Delivery of Drugs and Biologics in Nanoparticles _cedited by Pavan Muttil, Nitesh K. Kunda
250			_aFirst edition 2020
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (VIII, 277 páginas) _b52 ilustraciones, 42 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
490	0		_aAAPS Advances in the Pharmaceutical Sciences Series _x2210-7371 _v41
490	0		_aBiomedical and Life Sciences (Springer-11642)
505	0		_aSection I Background -- Introduction to Nanomedicine -- Characterization of Nanoparticles -- Section II Drugs and Biologics Encapsulated in Nanoparticles -- Routes of Delivery -- Small molecule Delivery -- Peptide and Protein Delivery -- Gene Delivery (siRNA/CRISPR) -- Phage Therapy -- Section III Diseases -- Non-infectious Diseases -- Infectious Diseases -- Cancer -- Section IV Host Interactions with Nanoparticles -- Interaction of Nanoparticles with Epithelial and Immune Cells -- Toxicity of Nanoparticles to the Host -- Nanoparticle Pharmacokinetics and Pharmacodynamics -- Section V MIscellanous -- Nanoparticles as Theranostics -- Regulatory Perspectives -- Manufacturing Scale-up of Nanoparticles.
520	3		_aThis book focuses on the application of nanotechnology to deliver drugs and biological agents by the mucosal routes of administration i.e. nasal, pulmonary, buccal, and oral routes.It provides an overview of nanotechnology in drug delivery with a description of different types of nanoparticles, methods of preparation and characterization, and functionalization for site-specific drug delivery. Mucosal Delivery of Drugs and Biologics in Nanoparticles emphasize the use of nanoparticles in treating various cancers and infectious diseases. It broadens the use of nanoparticles by including biologics, including vaccines and immunotherapies, apart from drugs. It acknowledges the concerns around the potential toxicity of nanoparticles to the host; few chapters will discuss the biodistribution of these nanoparticles when mucosal routes of administration are employed. Further, the interaction of nanoparticles with the host's immune cells is discussed. Moreover,it reviews the regulatory aspects of nanotechnology in product development, especially when delivered by the mucosal route of administration. Lastly, discusses the challenges and opportunities to manufacture nanoparticles on an industrial scale. This book will be the first of its kind to focus on the design, development and delivery of nanoparticles when administered by different mucosal routes.
988			_aSpringer_BiomedLife_31032020
650		7	_2embne _aSistemas de liberación de fármacos _9667667
650		7	_2embne _aTecnología farmacéutica _9161127
700	1		_aMuttil, Pavan. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aKunda, Nitesh K. _eeditor. _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service)
776	0	8	_iPrinted edition: _z9783030359096
776	0	8	_iPrinted edition: _z9783030359119
776	0	8	_iPrinted edition: _z9783030359126
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://dx.doi.org/10.1007/978-3-030-35910-2
942			_2lcc _cLE _n0
998			_b04/2020 _dz _eb _zSI